Therapeutic strategies to target TGF-β in the treatment of bone metastases

Jeroen T. Buijs, Patricia Juárez, Theresa Guise

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Bone is one of the most common organs to be affected in patients with metastatic cancer. These bone metastases are often accompanied by bone destruction, bone fractures, pain, and hypercalcemia. Transforming growth factor-β (TGF-β) is a major bone-derived factor that is released in active form upon osteoclastic bone resorption. TGF-β, in turn, stimulates bone metastatic cells to secrete factors that further drive osteolytic destruction of the bone adjacent to the tumor, categorizing TGF-β as a crucial factor responsible for driving the feed-forward vicious cycle of cancer growth in bone. Moreover, TGF-β activates epithelial-to-mesenchymal transition, increases tumor cell invasiveness and angiogenesis and induces immunosuppression. Blocking the TGF-β signaling pathway to interrupt this vicious cycle between tumor cells and bone offers a promising target for therapeutic intervention to decrease skeletal metastasis. In this review, preclinical and clinical data are evaluated for the potential use of TGF-β inhibitors in clinical practice to treat bone metastases.

Original languageEnglish
Pages (from-to)2121-2137
Number of pages17
JournalCurrent Pharmaceutical Biotechnology
Volume12
Issue number12
DOIs
StatePublished - Dec 2011

Fingerprint

Transforming Growth Factors
Neoplasm Metastasis
Bone and Bones
Therapeutics
Neoplasms
Growth Inhibitors
Epithelial-Mesenchymal Transition
Bone Development
Bone Fractures
Hypercalcemia
Bone Resorption
Immunosuppression
Pain

Keywords

  • Antibodies
  • Antisense oligonucleotides
  • Bone metastasis
  • Breast cancer
  • EMT
  • Prostate cancer
  • Small molecule inhibitors
  • TGF-β

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Biotechnology

Cite this

Therapeutic strategies to target TGF-β in the treatment of bone metastases. / Buijs, Jeroen T.; Juárez, Patricia; Guise, Theresa.

In: Current Pharmaceutical Biotechnology, Vol. 12, No. 12, 12.2011, p. 2121-2137.

Research output: Contribution to journalArticle

Buijs, Jeroen T. ; Juárez, Patricia ; Guise, Theresa. / Therapeutic strategies to target TGF-β in the treatment of bone metastases. In: Current Pharmaceutical Biotechnology. 2011 ; Vol. 12, No. 12. pp. 2121-2137.
@article{a48217f09ff4430983b297148a26f2d2,
title = "Therapeutic strategies to target TGF-β in the treatment of bone metastases",
abstract = "Bone is one of the most common organs to be affected in patients with metastatic cancer. These bone metastases are often accompanied by bone destruction, bone fractures, pain, and hypercalcemia. Transforming growth factor-β (TGF-β) is a major bone-derived factor that is released in active form upon osteoclastic bone resorption. TGF-β, in turn, stimulates bone metastatic cells to secrete factors that further drive osteolytic destruction of the bone adjacent to the tumor, categorizing TGF-β as a crucial factor responsible for driving the feed-forward vicious cycle of cancer growth in bone. Moreover, TGF-β activates epithelial-to-mesenchymal transition, increases tumor cell invasiveness and angiogenesis and induces immunosuppression. Blocking the TGF-β signaling pathway to interrupt this vicious cycle between tumor cells and bone offers a promising target for therapeutic intervention to decrease skeletal metastasis. In this review, preclinical and clinical data are evaluated for the potential use of TGF-β inhibitors in clinical practice to treat bone metastases.",
keywords = "Antibodies, Antisense oligonucleotides, Bone metastasis, Breast cancer, EMT, Prostate cancer, Small molecule inhibitors, TGF-β",
author = "Buijs, {Jeroen T.} and Patricia Ju{\'a}rez and Theresa Guise",
year = "2011",
month = "12",
doi = "10.2174/138920111798808293",
language = "English",
volume = "12",
pages = "2121--2137",
journal = "Current Pharmaceutical Biotechnology",
issn = "1389-2010",
publisher = "Bentham Science Publishers B.V.",
number = "12",

}

TY - JOUR

T1 - Therapeutic strategies to target TGF-β in the treatment of bone metastases

AU - Buijs, Jeroen T.

AU - Juárez, Patricia

AU - Guise, Theresa

PY - 2011/12

Y1 - 2011/12

N2 - Bone is one of the most common organs to be affected in patients with metastatic cancer. These bone metastases are often accompanied by bone destruction, bone fractures, pain, and hypercalcemia. Transforming growth factor-β (TGF-β) is a major bone-derived factor that is released in active form upon osteoclastic bone resorption. TGF-β, in turn, stimulates bone metastatic cells to secrete factors that further drive osteolytic destruction of the bone adjacent to the tumor, categorizing TGF-β as a crucial factor responsible for driving the feed-forward vicious cycle of cancer growth in bone. Moreover, TGF-β activates epithelial-to-mesenchymal transition, increases tumor cell invasiveness and angiogenesis and induces immunosuppression. Blocking the TGF-β signaling pathway to interrupt this vicious cycle between tumor cells and bone offers a promising target for therapeutic intervention to decrease skeletal metastasis. In this review, preclinical and clinical data are evaluated for the potential use of TGF-β inhibitors in clinical practice to treat bone metastases.

AB - Bone is one of the most common organs to be affected in patients with metastatic cancer. These bone metastases are often accompanied by bone destruction, bone fractures, pain, and hypercalcemia. Transforming growth factor-β (TGF-β) is a major bone-derived factor that is released in active form upon osteoclastic bone resorption. TGF-β, in turn, stimulates bone metastatic cells to secrete factors that further drive osteolytic destruction of the bone adjacent to the tumor, categorizing TGF-β as a crucial factor responsible for driving the feed-forward vicious cycle of cancer growth in bone. Moreover, TGF-β activates epithelial-to-mesenchymal transition, increases tumor cell invasiveness and angiogenesis and induces immunosuppression. Blocking the TGF-β signaling pathway to interrupt this vicious cycle between tumor cells and bone offers a promising target for therapeutic intervention to decrease skeletal metastasis. In this review, preclinical and clinical data are evaluated for the potential use of TGF-β inhibitors in clinical practice to treat bone metastases.

KW - Antibodies

KW - Antisense oligonucleotides

KW - Bone metastasis

KW - Breast cancer

KW - EMT

KW - Prostate cancer

KW - Small molecule inhibitors

KW - TGF-β

UR - http://www.scopus.com/inward/record.url?scp=84855235898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855235898&partnerID=8YFLogxK

U2 - 10.2174/138920111798808293

DO - 10.2174/138920111798808293

M3 - Article

VL - 12

SP - 2121

EP - 2137

JO - Current Pharmaceutical Biotechnology

JF - Current Pharmaceutical Biotechnology

SN - 1389-2010

IS - 12

ER -